Tenofovir alafenamide (TAF), a pro-drug of tenofovir disoproxil fumarate (TDF) is associated to higher intracellular concentration of tenofovir diphosphate and 91% lower serum concentration of tenofovir, compared to TDF, with less renal and bone toxicity. • Switching TDF to TAF in randomized clinical trials has shown: • Variable eGFR improvement; • Marginal benefit in safety with unboosted regimes, according to a recent meta-analysis1 . • Reversibility of renal function when TDF is discontinued is matter of debate: ∼37-60% reversibility in observational studies2-4 .
Evolution and reversibility of renal function after switch from TDF to TAF regimens
Nunnari G.;Pellicanò G. F.
2019-01-01
Abstract
Tenofovir alafenamide (TAF), a pro-drug of tenofovir disoproxil fumarate (TDF) is associated to higher intracellular concentration of tenofovir diphosphate and 91% lower serum concentration of tenofovir, compared to TDF, with less renal and bone toxicity. • Switching TDF to TAF in randomized clinical trials has shown: • Variable eGFR improvement; • Marginal benefit in safety with unboosted regimes, according to a recent meta-analysis1 . • Reversibility of renal function when TDF is discontinued is matter of debate: ∼37-60% reversibility in observational studies2-4 .File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
